Chlorine dioxide CASRN 10049-04-4 | IRIS

IRIS

System	RfD (mg/kg-day)	Basis	PoD	Composite UF	Confidence
Nervous, Developmental	3 x 10 ^-2	Neurodevelopmental effects	NOAEL : 3 mg/kg-day	100	Medium/High

System	RfC (mg/m³)	Basis	PoD	Composite UF	Confidence
Respiratory, Cardiovascular	2 x 10 ^-4	Vascular congestion and peribronchial edema	LOAEL (HEC): 6.4 x 10^-1 mg/m³	3000	Low

Weight of Evidence for Cancer (PDF) (25 pp, 177 K) Last Updated: 10/12/2000

WOE Characterization	Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity)	Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Carcinogenic potential cannot be determined	Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996)

Basis:

Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located.
This may be a synopsis of the full weight-of-evidence narrative.

Not assessed under the IRIS Program.

Not assessed under the IRIS Program.